references:
  title: References
  items:
    - Patel V, Chowdhury R, Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease. <em>Curr Opin Nephrol Hypertens</em>. 2009;18(2):99-106.
    - Boertien WE, Meijer E, Li J, et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease results from the CRISP cohort. <em>Am J Kidney Dis</em>. 2013;61(3):420-429.
    - Chapin HC, Caplan MJ. The cell biology of polycystic kidney disease. <em>J Cell Biol</em>. 2010;191(4):701-710.
    - Yamaguchi T, Pelling JC, Ramaswamy NT, et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. <em>Kidney Int</em>. 2000;57(4):1460-1471.
    - Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease the major factor determining clinical outcomes. <em>Clin J Am Soc Nephrol</em>. 2006;1(1):148-157.

